

Amendment

The following listing of claims will replace all prior versions and listings of claims in the application.

Listing of the Claims:

1. (Previously Presented) A composition comprising an isolated hyperimmune serum-reactive antigen fragment consisting of an amino acid sequence of 399-417, 503-519, 544-563, 489-556, 386-458, or 458-624 of SEQ ID NO:364.
2. (Currently Amended) The composition of claim 1, wherein the hyperimmune serum-reactive antigen fragment binds to anti-S.-agalactiae-serum and anti-S.-agalactiae-serum.
3. (Previously Presented) The composition of claim 1, further defined as comprising at least two different hyperimmune serum-reactive antigen fragments.
4. (Currently Amended) The composition of claim 3, wherein the at least two different hyperimmune serum-reactive antigen fragments both bind to anti-S.-agalactiae-serum and anti-S.-agalactiae-serum.
5. (Previously Presented) The composition of claim 1, further comprising an immunostimulatory substance.
6. (Currently Amended) The composition of claim 5, wherein the immunostimulatory substance is a polycationic polymer, an immunostimulatory non-methylatednon-methylated deoxynucleotide (ODN), a peptide containing at least two LysLeuLys motifs, alum, or a Freund's complete or incomplete adjuvant.
7. (Previously Presented) A composition comprising:
 - (a) an isolated hyperimmune serum-reactive antigen fragment consisting of an amino acid sequence of 399-417, 503-519, 544-563, 489-556, 386-458, or 458-624 of SEQ ID NO:364; and
 - (b) an immunostimulatory substance.